Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective To determine the cost effectiveness of intensive follow up compared with conventional follow up in patients with colorectal cancer. Design Incremental cost effectiveness analysis recognising differences in follow up strategies, based on effectiveness data from a meta-analysis of five randomised trials. Setting United Kingdom. Main outcome measures Taking a health service perspective, estimated incremental costs effectiveness ratios for each life year gained for five trials and four trials designed for early detection of extramural recurrences (targeted surveillance). Results Based on five year follow up, the numbers of life years gained by intensive follow up were 0.73 for the five trial model and 0.82 for the four trial model. For the five trials, the adjusted net (extra) cost for each patient was £2479 (€3550; $4288) and for each life year gained was £3402, substantially lower than the current threshold of NHS cost acceptability (£30 000). The corresponding values for the four trial model were £2529 and £3077, suggesting that targeted surveillance is more cost effective. The main predictor of incremental cost effectiveness ratios was surveillance costs rather than treatment costs. Judged against the NHS threshold of cost acceptability, the predicted incremental cost threshold was ninefold and the effectiveness threshold was 3%. Conclusions Based on the available data and current costs, intensive follow up after curative resection for colorectal cancer is economically justified and should be normal practice. There is a continuing need to evaluate the efficacy of specific surveillance tools: this study forms the basis for economic evaluations in such trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Research works printed but not linked: 34
- Kievit, 1995, Detection of recurrence after surgery for colorectal cancer., Eur J Cancer, 31, 1222, 10.1016/0959-8049(95)00155-C · DOI
- Scholefield, 2002, Guidelines for follow up after resection of colorectal cancer., Gut, 51, V3, 10.1136/gut.51.suppl_5.v3 · DOI
- 10.1136/bmj.324.7341.813 · DOI · Paper page
- Jeffrey GM Hickey BE Hider P . Follow-up strategies for patients treated for non-metastatic colorectal cancer. In: Cochrane Library, Issue 1. Oxford: Update Software, 2002. · DOI · Paper page
- 10.1053/ejso.2001.1250 · DOI · Paper page
- Mella, 1997, Surgeons' follow-up practice after resection of colorectal cancer., Ann R Coll Surg Engl, 79, 206
- Bruinvels, 1995, Follow-up after colorectal cancer: current practice in the Netherlands., Eur J Surg, 161, 827
- 10.1007/BF02307079 · DOI
- 10.1001/archsurg.1995.01430100040009 · DOI · Paper page
- 10.1007/BF02054122 · DOI · Paper page
- 10.1016/S0016-5085(98)70626-2 · DOI · Paper page
- 10.1007/BF02239434 · DOI · Paper page
- 10.1002/bjs.1800840523 · DOI · Paper page
- 10.1136/bmj.323.7310.423 · DOI
- 10.1136/bmj.325.7373.1135 · DOI · Paper page
- 10.1016/S0140-6736(02)08268-5 · DOI · Paper page
- 10.1056/NEJMoa021633 · DOI · Paper page
- Kievit, 2002, Follow-up of patients with colorectal cancer: numbers needed to test and treat., Eur J Cancer, 38, 986, 10.1016/S0959-8049(02)00061-8 · DOI · Paper page
- 10.1046/j.1463-1318.2003.00410.x · DOI
- 10.1007/BF02235044 · DOI · Paper page
- 10.1136/bmj.323.7324.1300 · DOI · Paper page
- Torgerson, 1999, Economics notes: discounting., BMJ, 319, 914, 10.1136/bmj.319.7214.914 · DOI
- 10.1001/jama.1995.03520470045030 · DOI · Paper page
- 10.1023/A:1008265614183 · DOI
- 10.1046/j.1525-1497.1997.012005318.x · DOI
- 10.1097/00000658-199807000-00009 · DOI · Paper page
- Beart, 2000, Follow-up: does it work? Can we afford it?, Surg Oncol Clin N Am, 9, 827, 10.1016/S1055-3207(18)30122-4 · doi:10.1016/s1055-3207(18)30122-4
- Van den Hout, 2002, Cost-effectiveness analysis of colorectal cancer treatments., Eur J Cancer, 38, 953, 10.1016/S0959-8049(02)00053-9 · DOI
- Stiggelbout, 1997, Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up., Br J Cancer, 75, 914, 10.1038/bjc.1997.161 · DOI · Paper page
- Renehan AG Egger M Saunders MP Whynes D O'Dwyer ST . Intensive follow-up after colorectal cancer. Recent successes and future challenges. In: Cunningham D Topham C Miles A eds. The effective management of colorectal cancer, 4th ed.. London: Aesculapius Medical Press,.
- 10.1023/A:1008999403069 · DOI
- 10.1002/(SICI)1099-1050(199802)7:1<21::AID-HEC306>3.0.CO;2-9 · DOI
- 10.1080/003655299750026254 · DOI · Paper page
- 10.1136/jms.6.3.119 · DOI
Cited by
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Weitz, J., Koch, M., Debus, J., Höhler, T., Galle, P. R., & Büchler, M. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17706-x · Cited by 1,098
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., Hider, P. N., & See, A. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub3 · Cited by 640
Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 360
Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis
Tjandra, J. J., & Chan, M. K. Y. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9030-5 · Cited by 342
Metadata
- Authors
- Renehan, A. G., Dwyer O', S. T., & Whynes, D. K.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-01-08
- Volume
- 328
- Issue
- 7431
- Pages
- 81
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2142247257
- Cited by
- 112
- References
- 1
- FWCI
- 22.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.